- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2012. The next inflection point is the US patent expiry in August 2027, which will allow generic competition.
- Why 4/10
- Xtandi is an already-approved, marketed drug with no pending PDUFA date or pivotal readout in the next ~12 months. The next hard catalyst is the US patent expiry in August 2027, which is a known commercial headwind rather than a binary regulatory event. For Pfizer, Xtandi is one of many products in a ~$62B+ revenue portfolio, so even a major label decision would move the stock modestly. ImpactScore 4 reflects an approved drug with no imminent binary catalyst.
The next major event for Xtandi is the US composition-of-matter patent expiry in August 2027, which opens the door to generic competition and will pressure revenue. In the nearer term, watch for Pfizer's Q4 2026 earnings (early Feb 2027) for Xtandi sales trends and any update on the talazoparib combo uptake. The ENZARAD trial failure in high-risk localized prostate cancer removes one expansion opportunity.
Price Chart
Executive Summary
Xtandi (enzalutamide) is a blockbuster oral androgen receptor inhibitor for prostate cancer, co-developed and co-marketed by Pfizer (NYSE: PFE) and Astellas. First approved by the FDA in 2012, it now holds four approved indications spanning metastatic and non-metastatic, castration-resistant and castration-sensitive prostate cancer. Global sales reached approximately $6 billion in Astellas' FY2025, but the franchise faces a major patent cliff: the core US composition-of-matter patent expires in August 2027. On October 26, 2026, the FDA approved a talazoparib (Talzenna) plus Xtandi combination for HRR-mutated metastatic prostate cancer based on the TALAPRO-3 trial. However, the Phase 3 ENZARAD trial (published October 2026) failed to show a benefit in high-risk localized prostate cancer. For Pfizer, Xtandi is a meaningful but non-dominant product within a diversified ~$62B+ revenue portfolio, and the stock's primary drivers extend well beyond this single drug.
How It Works
Xtandi is an androgen receptor inhibitor. It works by blocking the effects of male hormones (androgens like testosterone) on prostate cancer cells. Since prostate cancer cells need androgens to grow, blocking them can slow or stop the cancer's progression. It is taken as a daily oral pill.
Trial Status
Xtandi is FDA-approved across four prostate cancer indications. The most recent approval (October 26, 2026) was for talazoparib plus enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, supported by the Phase 3 TALAPRO-3 trial. The Phase 3 ENZARAD trial in high-risk localized prostate cancer failed to meet its primary endpoint (metastasis-free survival, HR 0.88, p=0.34).
The Two-Sided Case
Upcoming Catalysts
- US composition-of-matter patent expiry on August 13, 2027, which will permit generic enzalutamide entry.
- Pfizer Q4 2026 earnings (expected early February 2027) for Xtandi sales trends and talazoparib combo uptake.
- Potential label expansion decisions in ex-US markets for the talazoparib + enzalutamide combination.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report